Media.Player

Targeting B Cells in Prostate Cancer

Detailed Technology Description

This invention features methods to reduce androgen-independent prostate cancer. Currently, the most common way to treat primary non-metastatic prostate cancer entails treatment with anti-androgen drugs. In addition, surgical removal or radioablation are also practiced. While these procedures are effective, a major problem is the re-emergence of androgen independent cancer a few years later. Thus, what are needed are methods to reduce (including delay and/or complete inhibition of) the re-emergence of hormone resistant cancer. The inventors have demonstrated in mouse models that B cells remain in the tumor environment, even after castration. These B cells have been shown to assist in the re-emergence of the tumor. In vitro, the same phenomenon has been observed in 90 percent of the samples obtained from humans with malignant prostate cancer. By removing the B cell population, re-emergence of disease is significantly delayed. To older men (the most likely patient population to get prostate cancer), the delay of several years to re-emergence could be considered significant.

Supplementary Information

Patent Number: US20140086918A1
Application Number: US13982083A
Inventor: Karin, Michael | Ammirante, Massimo | Kuraishy, Ali
Priority Date: 31 Jan 2011
Priority Number: US20140086918A1
Application Date: 26 Aug 2013
Publication Date: 27 Mar 2014
IPC Current: A61K004748 | A61K0031381 | A61K0031437 | A61K003817
US Class: 4241341 | 4241731 | 5140195 | 514292 | 514447
Assignee Applicant: The Regents of the University of California
Title: Methods for Inhibiting Prostate Cancer
Usefulness: Methods for Inhibiting Prostate Cancer
Summary: The method is useful for reducing one or more of growth of castration resistant prostate cancer cells in a tissue and metastasis of Cap cells in a tissue, in a mammalian subject, and reducing androgen-induced growth of prostate epithelial cells in a mammalian subject, preferably a human (claimed). No biological data given.
Novelty: Reducing growth of castration resistant prostate cancer cells in a tissue and metastasis of castration resistant prostate cancer cells in a tissue, in a mammalian subject, comprises, administering a compound to the subject

Industry

Disease Diagnostic/Treatment

Sub Category

Cancer/Tumor

Application No.

9433686

Others

State Of Development

A patent application has been filed on this technology.

Related Materials

Ammirante M, Luo JL, Grivennikov S, Nedospasov S, Karin M. (2010) B-Cell-Derived Lymphotoxin Promotes Castration-Resistant Prostate Cancer. Nature ;464(7286):302-5.

Tech ID/UC Case

19208/2009-172-0

Related Cases

2009-172-0

*Abstract

None

*IP Issue Date

Sep 6, 2016

*Principal Investigator

Name: Massimo Ammirante

Department:

Name: Michael Karin

Department:

Name: Ali Kuraishy

Department:

Country/Region

USA